WT-1
PreclinicalBiologic
WT-1 is one of 35 biologic programs targeting Myeloid Neoplasm. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
38 competitors in Myeloid Neoplasm
#DrugCompanyPhaseTrials
1PEGASYS
Ppharmaand GmbH
Phase 3
Cytosar
TevaPhase 2
Novantrone
PfizerPhase 2
Fludara
SanofiPhase 2
Neoral
NovartisPhase 2
Cellcept
RochePhase 2
Leustatin
EMD SeronoPhase 2
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Idhifa
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Rapamune
PPrism Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for WT-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details